Trial intelligence / Profile preview

2LEBV and 2LXFS for asthenia in EBV infection

2024-514222-24-00Phase 4Authorised

Sponsor: Labo'Life
Start: Jun 2024
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
Countries: 1

Overview

Phase 4, randomised, double-blind trial in Epstein-Barr virus infection comparing 2LEBV, 2LXFS and Placebo (3 arms). Planned start Jun 2024; status: authorised.

Drugs

2LEBV2LXFS

Conditions

Epstein-Barr virus infection

Beyond the preview

Go deeper on 2024-514222-24-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514222-24-00.